Why the study?
Potential antiviral therapies targeting human metapneumovirus needed to be identified by evaluating FDA-approved antiviral drugs and control compounds.
Do FDA-approved antiviral drugs like Remdesivir and Peramivir show potential for repurposing against human metapneumovirus in computational models?
Do FDA-approved antiviral drugs like Remdesivir and Peramivir show potential for repurposing against human metapneumovirus in computational models?
Computational modeling identifies Remdesivir and Peramivir as promising candidates for repurposing against human metapneumovirus based on favorable binding energies and ADMET profiles.
This study leverages advanced computational methodologies to identify potential antiviral therapies targeting human metapneumovirus (HMPV), focusing on FDA-approved antiviral drugs and control compounds. A comprehensive computational framework, encompassing virtual screening, molecular docking, molecular dynamics (MD) simulations, density functional theory (DFT) analysis, and ADMET profiling, was employed. Key findings highlight Remdesivir and Peramivir as the most promising candidates, with superior binding energies (−9.5 kcal/mol and - 9.2 kcal/mol, respectively), stable interaction profiles, and robust pharmacological properties. Molecular dynamics revealed exceptional stability for Remdesivir, with the lowest RMSD (0.20 nm), and pharmacophore analysis emphasized its strong hydrogen bonding and hydrophobic interactions. ADMET profiling confirmed their high bioavailability (85% ± 3 for Remdesivir) and low toxicity, positioning these drugs for repurposing against HMPV. This integrative study underscores the potential of computational tools in streamlining drug discovery and advancing therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Dubey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: